Epidemiology and overall survival of de novo and transformed neuroendocrine prostate cancer: a two-nation population-based study of 1,465 patients from the United States and England
Endocrine-Related Cancer · 2026
DOI: 10.1530/erc-26-0268 ↗Kurz gefasst
Fachartikel in der Zeitschrift Endocrine-Related Cancer, 2026. Verfasst von Sunyoung Choi und 7 weiteren Autor:innen. Beteiligte Einrichtung: Hampshire Hospitals NHS Foundation Trust , Basingstoke, United Kingdom. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Carcinoma, Neuroendocrine, Neuroendocrine Tumors. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 50 Literaturangaben.
Abstract (Originalsprache)
Neuroendocrine prostate cancer (NEPC) is a rare and aggressive variant of prostate cancer (PC) that can be de novo (d-NEPC) or transform from prior prostate adenocarcinoma (PCa) as treatment-emergent NEPC (t-NEPC). This study aimed to study the clinical characteristics and overall survival (OS) of NEPC using data from the SEER and NCRAS registries and to compare OS of d-NEPC and t-NEPC. A total of 1,465 patients with NEPC were extracted from SEER (n = 990, 2010–2022) and NCRAS (n = 475, 2010–2021). Patients were classified as t-NEPC if preceded by a documented PCa. The primary outcome was OS measured from the date of NEPC diagnosis. Kaplan–Meier analysis, the log-rank test, and Cox regression were performed for SEER, NCRAS, and pooled cohorts. t-NEPC represented 9.9% in NCRAS and 15.2% in SEER. Small cell carcinoma was the most common subtype (80.2% NCRAS, 74.7% SEER). Median time to transformation was 4.63 years in NCRAS and 5 years in SEER. In the pooled cohort, median OS was 9 months for d-NEPC and 7 months for t-NEPC (log-rank P < 0.001). The 60-month OS was 7.9% for d-NEPC and 4.0% for t-NEPC. In the pooled multivariable Cox regression, t-NEPC was independently associated with worse OS (aHR: 1.30, 95% CI: 1.11–1.53, P = 0.001). Data source was not associated with OS (aHR: 1.08, P = 0.206), indicating comparable OS between the USA and England. In this bi-national, population-based study, t-NEPC was associated with worse OS than d-NEPC. OS for NEPC was comparable between the USA and England. These findings support distinguishing d-NEPC from t-NEPC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Hampshire Hospitals NHS Foundation Trust , Basingstoke, United Kingdom.
- St. George's University School of Medicine , St George's, Grenada.
- Cambridge University Hospitals NHS Foundation Trust , Cambridge, United Kingdom.
- University of Winchester , Winchester, United Kingdom.
- King's Health Partners Neuroendocrine Tumour Centre , London, United Kingdom.
ORCID-Profile: Mohamed Mortagy, John Ramage
Zitieren
APA
Choi, S., Mortagy, M., Tan, K. S., White, B. E., Paisey, S., Abdelhameed, A., Rous, B., & Ramage, J. (2026). Epidemiology and overall survival of de novo and transformed neuroendocrine prostate cancer: a two-nation population-based study of 1,465 patients from the United States and England. Endocrine-Related Cancer. https://doi.org/10.1530/erc-26-0268
Vancouver
Choi S, Mortagy M, Tan KS, White BE, Paisey S, Abdelhameed A, et al. Epidemiology and overall survival of de novo and transformed neuroendocrine prostate cancer: a two-nation population-based study of 1,465 patients from the United States and England. Endocrine-Related Cancer. 2026. doi:10.1530/erc-26-0268
BibTeX
@article{Choi2026,
author = {Choi, Sunyoung and Mortagy, Mohamed and Tan, Ker Shiong and White, Benjamin E and Paisey, Sangeeta and Abdelhameed, Aya and Rous, Brian and Ramage, John},
title = {Epidemiology and overall survival of de novo and transformed neuroendocrine prostate cancer: a two-nation population-based study of 1,465 patients from the United States and England},
journal = {Endocrine-Related Cancer},
year = {2026},
doi = {10.1530/erc-26-0268}
}
EUVIMED